Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

preview_player
Показать описание
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

  1. GRACE - Global Resource for Advancing Cancer Education
  2. GRACE
  3. cancerGRACE
  4. GRACEcast
  5. Dr. Jack West
  6. Swedish Cancer Institute
Рекомендации по теме
Options for EGFR 0:03:24

Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

Advancing Care for 0:53:55

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine Strategies

New Treatment Option 0:01:57

New Treatment Option for EGFR Mutated Lung Cancer

What Are the 0:03:22

What Are the Choices for EGFR Mutation-Positive AR in Patients W/out a T790M Mutation?

Combinations and Other 0:04:26

Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC

Sequential treatment with 0:06:28

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

EGFR-Mutant Lung Cancer 0:14:24

EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient F...

2021 West Oncology 0:20:34

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2

Trials in EGFR 0:10:38

Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer

Dr. Konduri on 0:01:37

Dr. Konduri on Treatment Options for Patients With EGFR-Mutant NSCLC

Tumor clonality in 0:10:30

Tumor clonality in EGFR mutation-positive NSCLC

Sequential afatinib and 0:06:43

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

Therapeutic strategies for 0:02:23

Therapeutic strategies for EGFR-mutated lung cancer

2023 Best of 0:30:32

2023 Best of Lung: Targeted Therapies in Lung Cancer

Treatment Options for 0:01:59

Treatment Options for EGFR-positive Lung Cancer

Adjuvant therapy for 0:14:30

Adjuvant therapy for EGFR mutant NSCLC

Treatment Options for 0:24:36

Treatment Options for EGFR T790M Negative Acquired Resistance

How, when, and 0:17:27

How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC

EGFR mutation positive 0:23:10

EGFR mutation positive tumors: Treatment strategies in front line and at relapse

Understanding NSCLC Treatment 0:05:03

Understanding NSCLC Treatment When You Have an EGFR Mutation

Molecular Testing for 1:01:27

Molecular Testing for EGFR Mutations: What Pathologists Need to Know

Surgery Options for 0:05:55

Surgery Options for NSCLC & I-O Therapy in EGFR-Mutations

Targeted treatment with 0:20:24

Targeted treatment with EGFR TKIs: Front line options

Emerging Options for 0:13:53

Emerging Options for T790M-Positive Acquired Resistance